The US Agency for Healthcare Research and Quality has published data showing a massive increase in Medicare outpatient payments for prescription medicines, up from $5.9 billion in 2005 to $44.3 billion in the following year. The figures confirm the effect of the introduction of the Medicare Part D prescription drug benefit in May 2006 (Marketletters passim). The AHRQ also estimated that the eligible population saw the following shifts in coverage: Medicare's outgoings rose from 7% to 45%; Medicaid's fell from 15.5% to 1%; and private insurers' dropped from 25% to 16.5%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze